| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
RBC Capital analyst Lisa Walter reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and maintains $26 price...
-SEC Filing
Jim Cramer doesn't recommend buying more AppLovin stock. "Let's take a little off the table just to be prudent,"...
Roth Capital analyst Salveen Richter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and lowers the price targe...